IRIS
PERNO, CARLO-FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 143.999
AS - Asia 16.265
EU - Europa 14.882
SA - Sud America 2.569
AF - Africa 379
OC - Oceania 134
Continente sconosciuto - Info sul continente non disponibili 45
Totale 178.273
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 143.471
SG - Singapore 7.836
CN - Cina 2.796
DE - Germania 2.136
RU - Federazione Russa 2.119
BR - Brasile 2.091
UA - Ucraina 1.872
IT - Italia 1.820
HK - Hong Kong 1.491
SE - Svezia 1.370
IE - Irlanda 1.231
VN - Vietnam 1.230
FI - Finlandia 1.092
FR - Francia 1.014
GB - Regno Unito 771
PL - Polonia 728
KR - Corea 704
BD - Bangladesh 550
JP - Giappone 375
CA - Canada 306
IQ - Iraq 269
IN - India 226
AR - Argentina 173
ID - Indonesia 161
NL - Olanda 146
AU - Australia 131
MX - Messico 109
ZA - Sudafrica 109
BE - Belgio 106
AT - Austria 99
TR - Turchia 97
ES - Italia 94
EC - Ecuador 87
CZ - Repubblica Ceca 86
PK - Pakistan 73
PH - Filippine 68
IR - Iran 65
CO - Colombia 49
CL - Cile 45
UZ - Uzbekistan 43
CM - Camerun 41
VE - Venezuela 40
EU - Europa 34
KE - Kenya 34
MA - Marocco 34
AE - Emirati Arabi Uniti 33
CH - Svizzera 33
PY - Paraguay 29
EG - Egitto 25
NP - Nepal 25
RO - Romania 25
SA - Arabia Saudita 25
TN - Tunisia 25
MY - Malesia 24
PE - Perù 23
DZ - Algeria 22
IL - Israele 22
JM - Giamaica 22
LT - Lituania 21
JO - Giordania 19
GR - Grecia 16
KZ - Kazakistan 16
PT - Portogallo 15
UY - Uruguay 15
BG - Bulgaria 14
BO - Bolivia 14
HN - Honduras 14
KG - Kirghizistan 14
TH - Thailandia 14
AZ - Azerbaigian 13
GT - Guatemala 13
DK - Danimarca 12
CR - Costa Rica 11
HU - Ungheria 11
TW - Taiwan 11
DO - Repubblica Dominicana 10
ET - Etiopia 10
GH - Ghana 10
LB - Libano 10
NG - Nigeria 10
LK - Sri Lanka 9
CI - Costa d'Avorio 8
DM - Dominica 8
OM - Oman 8
TT - Trinidad e Tobago 8
AL - Albania 7
PS - Palestinian Territory 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AO - Angola 6
BY - Bielorussia 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
BB - Barbados 5
HR - Croazia 5
LY - Libia 5
MN - Mongolia 5
NI - Nicaragua 5
PA - Panama 5
QA - Qatar 5
SN - Senegal 5
Totale 178.173
Salva come PNG Salva come JPEG
Città #
Woodbridge 41.750
Wilmington 36.809
Houston 32.044
Singapore 4.125
Fairfield 3.940
Ann Arbor 3.352
Ashburn 2.582
Chandler 1.981
San Jose 1.950
Jacksonville 1.680
Seattle 1.663
Hong Kong 1.467
Cambridge 1.358
Dublin 1.162
Beijing 1.090
Council Bluffs 920
Medford 912
Santa Clara 803
Dearborn 668
Helsinki 667
Kraków 626
New York 549
Rome 549
Moscow 534
Los Angeles 530
The Dalles 494
Dallas 441
Lawrence 429
Ho Chi Minh City 373
Tokyo 314
Hanoi 299
Buffalo 273
Mülheim 270
Milan 228
São Paulo 221
San Diego 211
Menlo Park 206
Lauterbourg 191
Zhengzhou 161
Munich 151
Orem 127
London 121
Nuremberg 121
Jakarta 116
Phoenix 110
Boardman 109
Chicago 108
Falls Church 107
Brussels 101
University Park 86
San Francisco 85
Redwood City 79
Dong Ket 78
Frankfurt am Main 78
Palo Alto 76
Baghdad 75
Norwalk 75
Toronto 73
Guangzhou 71
Columbus 68
Chennai 67
Warsaw 67
North Bergen 66
Rio de Janeiro 66
Montreal 65
Mountain View 65
Shanghai 64
Nanjing 62
Redondo Beach 62
San Mateo 62
Atlanta 60
Creede 59
Verona 59
Amsterdam 58
Porto Alegre 58
Brooklyn 55
Haiphong 55
Johannesburg 54
Denver 51
Brno 49
Poplar 47
Saint Petersburg 44
Hefei 42
Vancouver 41
Vienna 41
Boston 40
Da Nang 40
Kunming 40
Stockholm 39
Lappeenranta 37
Sydney 37
Belo Horizonte 36
Melbourne 36
Brasília 34
Sulaymaniyah 33
Naples 32
Tashkent 32
Colorado Springs 31
Curitiba 31
Olomouc 31
Totale 151.785
Salva come PNG Salva come JPEG
Nome #
1,2,3-TRIAZOLE-[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOL 2'',2''-DIOXIDE) (TSAO) ANALOGS - SYNTHESIS AND ANTI-HIV-1 ACTIVITY 1.102
Antibiotic susceptibility of vancomyin and nitrofurantoin in Staphylococcus aureus isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan 777
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 599
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 577
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 575
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 569
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 552
KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy 544
Progesterone and Melanoma Cells: An Old Story Suspended between Life and Death 535
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 534
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 534
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 533
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 530
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes 528
A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication 527
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 527
Therapeutic strategies towards HIV-1 infection in macrophages 519
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus? 514
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 513
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 510
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 510
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 510
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity 509
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 508
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 507
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 506
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 499
Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir 498
Influenza virus A (H5N1): A pandemic risk? 497
Activity of the (R)-Enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems 497
Thymosin alpha 1 and HIV-1: Recent advances and future perspectives 497
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay 496
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 494
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 492
Understanding HIV compartments and reservoirs 492
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection 491
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection 491
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 491
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 490
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 489
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 488
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 487
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 487
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 486
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 486
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs 485
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 485
Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV 484
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007 484
Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro 484
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 483
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 482
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 482
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 481
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 481
HIV-1-associated dementia during HAART therapy 480
Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy 479
Novel drug resistance mutations in HIV: Recognition and clinical relevance 477
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines 477
Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus 477
Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models 477
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 476
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 475
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 474
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 474
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 473
Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage 472
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 472
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 470
Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient 469
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 469
Macrophage depletion induced by clodronate-loaded erythrocytes 469
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV 468
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir 468
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 468
A case of Italian HIV-2 infection: a genetic analysis 468
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 467
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 467
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 466
Glutathione inhibits HIV replication by acting at late stages of the virus life cycle 466
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. 466
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 465
Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1) 463
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 462
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes 461
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 461
Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients 461
Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients 461
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 461
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin 460
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 459
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 459
Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice 458
Antiviral profile of HIV inhibitors in macrophages: Implications for therapy 458
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 458
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression 457
Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique 457
Totale 49.978
Salva come PNG Salva come JPEG
Categoria #
all - tutte 394.794
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 394.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.019 233 358 337 253 210 523 206 179 764 480 232 1.244
2022/20235.987 665 415 201 716 465 1.332 426 454 482 110 498 223
2023/20242.031 267 195 142 72 258 344 88 83 55 89 35 403
2024/202511.964 417 2.601 1.198 655 364 688 1.213 536 1.077 714 1.402 1.099
2025/202620.066 1.391 873 2.267 1.592 1.531 811 2.543 2.703 2.220 1.866 1.174 1.095
2026/202780 80 0 0 0 0 0 0 0 0 0 0 0
Totale 179.567